The US Food and Drug Administration (FDA) has approved the use of Lannett’s Ondansetron, a generic version of GlaxoSmithKline’s Zofran.
The drug, administered in injection form, is used to treat postoperative and chemotherapy-induced nausea.
Arthur Bedrosian, president and chief executive officer of Lannett,said: “Ondansetron Injection is the first injectable product for whichLannett has filed an Abbreviated New Drug Application.
“The addition of an injectable drug to our product offering will enhance our ability to build our hospital-based business.”
Bedrosian added that the company had a pending application at the FDAor a single-dose vial of Ondansetron, for which approval is expectedshortly.
Lannett, founded in 1942, develops, manufactures, packages, markets anddistributes generic pharmaceutical products for a wide range ofindications.
Copyright Press Association 2010